Saturday 10 October 2026
Export all IDXG data to Excel Powerpack
Interpace Biosciences, Inc.
IDXG
Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024. In the quarter to June 2026, revenue fell 1.09%, EPS grew 104.1% and free cash flow fell 92.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.
6.00
0.00
0.00%
Follow IDXG
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 4 | 3 | 2 | 4 | 5 | 4 | 8 | 7 | 5 |
P/E ratio |
0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.42 | 0.04 |
Altman Z-Score |
— | — | — | — | — | — | — | — | (17.12) | (6.95) |
P/S ratio |
0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.05 | 0.03 |
P/FCF ratio |
0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.63 | 0.22 |
Altman Z″-Score (non-manufacturers) |
(12.06) | (4.32) | (16.44) | (15.37) | (19.97) | (21.52) | (54.04) | (59.50) | (47.82) | (16.52) |
P/Operating CF |
0.69 | 0.69 | 0.69 | 0.69 | 0.69 | 0.69 | 0.69 | 0.69 | 2.00 | 0.51 |
Beneish M-Score |
(2.74) | (1.70) | (2.20) | (2.74) | (3.79) | (2.98) | (2.63) | (2.98) | (1.05) | 2.07 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
EV/Sales |
0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.08 | 0.04 |
EV/EBITDA |
0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.42 | 0.29 |
EV/Operating CF |
0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.81 | 0.24 |
EV/FCF |
0.58 | 0.58 | 0.58 | 0.58 | 0.58 | 0.58 | 0.58 | 0.58 | 1.00 | 0.28 |
Quick Ratio |
0.17 | 2.30 | 1.79 | 0.73 | 0.63 | 0.48 | 0.69 | 0.75 | 0.94 | 1.60 |
Current Ratio |
0.26 | 2.45 | 2.04 | 0.95 | 0.77 | 0.78 | 0.85 | 0.91 | 1.11 | 1.94 |
Net Debt/EBITDA |
(3.73) | 6.11 | 0.69 | (0.03) | 0.16 | (7.76) | 1.05 | 0.13 | (0.16) | (0.50) |
Debt/Assets |
18.93% | 0.00% | 0.00% | 5.82% | 0.00% | 24.57% | 85.52% | 32.35% | 0.00% | 0.00% |
Debt/Equity |
1.21 | 0.00 | 0.00 | (0.67) | 0.00 | (0.22) | (0.22) | (0.08) | 0.00 | 0.00 |
Asset Turnover |
0.24 | 0.33 | 0.52 | 0.59 | 0.67 | 0.79 | 1.17 | 2.75 | 3.36 | 1.59 |
Operating CF/Net income |
0.91 | 1.25 | 0.68 | 0.70 | 0.47 | 0.58 | 0.35 | 1.94 | 0.74 | 0.24 |
Capex/Depreciation |
0.00 | (0.01) | (0.12) | (3.08) | (0.29) | (0.06) | (0.03) | (0.29) | (1.17) | (0.40) |
Interest Coverage |
(3.00) | (14.53) | — | (60.08) | (47.48) | (12.77) | (22.89) | 35.32 | 238.47 | — |
| (85.16%) | (52.66%) | (45.93%) | (495.47%) | 175.70% | 41.80% | 41.63% | (3.29%) | (21.60%) | 243.97% | |
| (15.22%) | (25.62%) | (29.99%) | (65.73%) | (60.65%) | (35.53%) | (80.72%) | 13.43% | 44.70% | 101.07% | |
ROIC |
(29.10%) | (15.94%) | (84.19%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 12.85% |
Return on Tangible Assets |
75.25% | (98.75%) | (128.46%) | (450.41%) | (910.56%) | 467.11% | 1,331.59% | (853.28%) | 247.64% | 395.10% |
Average Days of Receivables |
61.62 | 78.91 | 158.08 | 155.80 | 90.44 | 51.49 | 57.69 | 46.30 | 66.46 | 53.24 |
Research and Development Expense of Revenue |
12.59% | 9.19% | 9.70% | 11.60% | 8.63% | 4.51% | 2.21% | 1.59% | 1.44% | 1.66% |
Selling, General and Administrative Expense of Revenue |
122.02% | 98.89% | 78.08% | 105.20% | 84.72% | 60.04% | 63.13% | 48.95% | 45.05% | 50.10% |
Intangible Assets out of Total Assets |
0.87 | 0.62 | 0.40 | 0.47 | 0.43 | 0.06 | 0.05 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1.00% | 6.67% | 10.37% | 6.34% | 6.75% | 3.79% | 3.95% | 1.57% | 0.62% | 0.09% |
Graham Net Nets |
(63.65) | (63.65) | (63.65) | (63.65) | (63.65) | (63.65) | (63.65) | (63.65) | (2.21) | (1.45) |
Graham Number |
0.00 | 0.00 | 0.00 | 69.54 | 171.34 | 144.33 | 208.24 | 0.00 | 0.00 | 125.75 |
Earnings Yield |
406.62% | 406.62% | 406.62% | 406.62% | 406.62% | 406.62% | 406.62% | 406.62% | 238.38% | 2,260.62% |
Free Cash Flow Yield |
316.22% | 316.22% | 316.22% | 316.22% | 316.22% | 316.22% | 316.22% | 316.22% | 159.14% | 461.73% |
Revenue per Share |
360.47 | 50.42 | 38.88 | 32.33 | 40.21 | 40.04 | 37.56 | 46.37 | 53.48 | 43.77 |
Operating CF per Share |
(209.56) | (48.41) | (15.40) | (25.30) | (17.35) | (10.54) | (9.07) | 4.39 | 5.30 | 6.59 |
Capex per Share |
0.00 | (0.09) | (0.80) | (18.62) | (1.95) | (0.38) | (0.38) | (0.54) | (1.00) | (0.40) |
Free Cash Flow per Share |
(209.56) | (48.50) | (16.20) | (43.92) | (19.30) | (10.92) | (9.45) | 3.84 | 4.30 | 6.19 |
Cash per Share |
16.58 | 48.20 | 10.77 | 3.10 | 4.18 | 3.53 | 5.70 | 4.05 | 1.67 | 2.83 |
Shareholders Equity per Share |
179.92 | 126.45 | 27.43 | (5.98) | (36.09) | (51.29) | (74.41) | (64.33) | (2.53) | 25.27 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
179.92 | 126.45 | 27.43 | (5.98) | (36.09) | (51.29) | (74.41) | (64.33) | (2.53) | 25.27 |
Free Cash Flow |
(7.61) | (15.29) | (9.12) | (32.90) | (15.55) | (9.03) | (8.01) | 3.32 | 3.77 | 5.48 |
Working Capital |
(12.00) | 11.72 | 9.05 | (0.78) | (4.11) | (3.52) | (2.13) | (1.02) | 1.16 | 4.80 |
Capital Expenditures |
— | (0.03) | (0.45) | (13.95) | (1.57) | (0.31) | (0.32) | (0.47) | (0.88) | (0.36) |
Net Current Asset Value |
(31.01) | 6.08 | 2.04 | (39.51) | (60.64) | (68.68) | (66.90) | (58.24) | (5.24) | (1.57) |
EV/EBIT |
0.29 | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 | 0.46 | 0.35 |
Capex to Sales |
0.00 | 0.00 | 0.02 | 0.58 | 0.05 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 |
Price to Operating Income |
0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.29 | 0.27 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
4.83 | 5.82 | 4.54 | 0.66 | 0.75 | 17.34 | 24.99 | 2.08 | 0.55 | 0.62 |
Cash ROIC |
(50.58%) | (27.77%) | (42.40%) | (3,907.84%) | 60.50% | 30.06% | 17.98% | (6.94%) | (498.68%) | 22.02% |
Accounts Receivable Turnover |
5.22 | 5.63 | 3.39 | 2.44 | 3.53 | 5.22 | 6.56 | 7.92 | 6.89 | 5.46 |
Accounts Payable Turnover |
3.42 | 5.42 | 14.06 | 5.51 | 4.70 | 4.86 | 11.23 | 11.55 | 10.62 | 11.05 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
127.84 | 19.40 | 37.91 | 108.18 | 75.97 | 35.04 | 28.17 | 37.62 | 35.62 | 24.58 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
2.51 | 2.82 | 6.46 | 9.91 | 9.18 | 6.35 | 4.85 | 5.06 | 6.81 | 7.10 |
Average Payables |
1.94 | 1.36 | 0.73 | 2.88 | 4.61 | 2.94 | 1.21 | 1.30 | 1.60 | 1.32 |
Average Assets |
54.75 | 47.69 | 42.36 | 41.33 | 48.61 | 42.05 | 27.20 | 14.55 | 13.95 | 24.32 |
Average Common Equity |
9.78 | 23.20 | 27.66 | 5.48 | (16.78) | (35.75) | (52.74) | (59.31) | (28.88) | 10.07 |
Columns are period end dates · fundamentals updated 28 Sep 2026